ReviewTrends in molecular medicine2016
IL-17 in Chronic Inflammation: From Discovery to Targeting.
Review in Trends in molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
205 citing papers in PubMed, 1 synthesis or guideline pooled it, 395 citations in OpenAlex.
- Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Pooled it
- Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.Annals of the rheumatic diseases · 2021Trial
- Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.Clinical pharmacokinetics · 2018Trial
- Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis.Inflammopharmacology · 2018Trial
- The Effect of Whole-Body Cryotherapy at Different Temperatures on Proinflammatory Cytokines, Oxidative Stress Parameters, and Disease Activity in Patients with Ankylosing Spondylitis.Oxidative medicine and cellular longevity · 2018Trial
- Emerged N193S mutation of PA-X protein disabled the immunity of mucosal dendritic cells for regulating virulence of clade 2.3.4.4b H5 subtype virus.Emerging microbes & infections · 2026Article
- From screening to treatment:Microbiology spectrum · 2026Article
- DYRK kinases phosphorylate IL-17RA at S801.Serican journal of medicine · 2026Article
- Helicase A determines the transcription program of TScience advances · 2026Article
- Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial.Rheumatology and immunology research · 2026Article
- Bone marrow mesenchymal stromal cells metabolic reprogramming in systemic lupus erythematosus: remodeling of bone marrow microenvironment and regulation of immune cell fate.Frontiers in immunology · 2026Review
- The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment.Frontiers in immunology · 2026Article
- Vicenin-2 attenuates rosacea-like inflammation by inhibiting IL-17RA signaling.Frontiers in pharmacology · 2026Article
- Article
- The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.British journal of pharmacology · 2025Review
- Electroacupuncture Alleviates Cerebral Ischemia-Reperfusion Injury by Downregulating IL-17 A and Inhibiting Neurotoxic Astrocyte Activation.Neurochemical research · 2025Article
- Antisense oligonucleotides targeting IRF4 alleviate psoriasis.Acta pharmaceutica Sinica. B · 2025Article
- Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice.Chinese journal of integrative medicine · 2025Article
- Multimodal Function of Mesenchymal Stem Cells in Psoriasis Treatment.Biomolecules · 2025Review
- Deep insight into cytokine storm: from pathogenesis to treatment.Signal transduction and targeted therapy · 2025Review
145 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17 (IL-17) is a cytokine which elicits protection against extracellular bacterial and fungal infections and which plays important roles in inflammation. However, when produced in excess, it contributes to chronic inflammation associated with many inflammatory and autoimmune disorders. This has made IL-17 an attractive therapeutic target. The present review describes the structure of the IL-17 family, the IL-17 receptor complex, and the cells producing IL-17. The contributions of IL-17 to disease as well as new IL-17-based treatment options are discussed. Finally, the results of IL-17 or IL-17 receptor inhibitors in clinical trials are detailed. With a fruitful outlook, drug registration has now been granted for psoriasis psoriatic arthritis and ankylosing spondylitis, and also bears great potential in a growing number of conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.